Jennifer Johnston, PhD
President and Founder at Annoah Discovery
CSO and Co-Founder at An2H
Location: San Francisco, California, United States
Jennifer Johnston, PhD, has been interested in the Ub-proteasome pathway for the last 20 years, starting with work on protein folding and substrate degradation by the proteasome with Dr. A. Varshavsky. Subsequently, her work with Dr. R. Kopito resulted in the discovery and description of Aggresomes, the first example of cellular proteostasis and provided a link between the proteasome pathway and canonical neurodegeneration pathology phenotypes.† At Elan Pharmaceuticals, Dr. Johnston directly applied the tenets of Aggresome biology, protein folding and cellular proteostasis to basic research and drug discovery for Parkinsonís disease. In addition to serving as VP Research and Head of Exploratory Research, Dr. Johnston also led the Parkin Project, a drug discovery program focused on the identification of specific small molecule therapeutics that modulate the activity of Parkin E3 ligase.† Presently, Dr. Johnston is President and Founder of Annoah Discovery, a Biotech company focused on the modulation of the Ubiquitin pathway for critical unmet medical needs.